Non-Viral Gene-Edited Manufacturing to Advance TCR-T Therapies

• Non-viral gene-edited TCR gene integration for potent TCR-T cell therapies
• Scalable manufacturing inputs to support scale-out and reduce timelines to FIH products
• Enable scalable, cost-effective TCR-T therapy delivery to meet growing clinical demand

Speakers:

Reagan Jarvis

Chief Executive Officer & Co-Founder

Anocca